Company intelligence / Profile preview

Danstar Ferment

Zug, Zug, Switzerlandvitilevure-danstar.com ↗

Ownership: Private
Development stage: Commercial

Overview

Danstar Ferment AG develops and manufactures yeast-based products, industrial enzymes, microorganisms and their derivatives. It has commercialized a range of solutions across food ingredients, human/animal nutrition & health sectors. The company developed a nasal spray with clinical proof-of-concept efficacy against an unspecified disease. In December 2023 it acquired Evolva AG to expand its R&D presence in Switzerland.

Therapeutic areas: Metabolic DisordersImmunologyOther
Modalities: Microbial therapyEnzyme replacement therapyProteinSmall moleculeLive biotherapeutic product therapy
Industry: Biotech

Beyond the preview

Go deeper on Danstar Ferment.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Danstar Ferment.

Explore the full profile